ID   IDE_RAT                 Reviewed;        1019 AA.
AC   P35559;
DT   01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-1994, sequence version 1.
DT   02-OCT-2024, entry version 184.
DE   RecName: Full=Insulin-degrading enzyme;
DE            EC=3.4.24.56 {ECO:0000269|PubMed:10684867, ECO:0000269|PubMed:1445854, ECO:0000269|PubMed:14527953, ECO:0000269|PubMed:1836994, ECO:0000269|PubMed:21731629, ECO:0000269|PubMed:22049080};
DE   AltName: Full=Insulin protease;
DE            Short=Insulinase;
DE   AltName: Full=Insulysin {ECO:0000303|PubMed:21731629};
GN   Name=Ide;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=Wistar; TISSUE=Brain;
RX   PubMed=8425612; DOI=10.1016/0014-5793(93)81286-9;
RA   Baumeister H., Mueller D., Rehbein M., Richter D.;
RT   "The rat insulin-degrading enzyme. Molecular cloning and characterization
RT   of tissue-specific transcripts.";
RL   FEBS Lett. 317:250-254(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 898-995.
RC   STRAIN=Sprague-Dawley;
RX   PubMed=7678795; DOI=10.1210/endo.132.2.7678795;
RA   Kuo W.L., Montag A.G., Rosner M.R.;
RT   "Insulin-degrading enzyme is differentially expressed and developmentally
RT   regulated in various rat tissues.";
RL   Endocrinology 132:604-611(1993).
RN   [3]
RP   PARTIAL PROTEIN SEQUENCE, FUNCTION, CATALYTIC ACTIVITY, ACTIVITY ON ANP,
RP   SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=1836994; DOI=10.1111/j.1432-1033.1991.tb16374.x;
RA   Mueller D., Baumeister H., Buck F., Richter D.;
RT   "Atrial natriuretic peptide (ANP) is a high-affinity substrate for rat
RT   insulin-degrading enzyme.";
RL   Eur. J. Biochem. 202:285-292(1991).
RN   [4]
RP   FUNCTION, CATALYTIC ACTIVITY, AND ACTIVITY ON ANP; BNP AND CNP.
RX   PubMed=1445854; DOI=10.1021/bi00160a026;
RA   Mueller D., Schulze C., Baumeister H., Buck F., Richter D.;
RT   "Rat insulin-degrading enzyme: cleavage pattern of the natriuretic peptide
RT   hormones ANP, BNP, and CNP revealed by HPLC and mass spectrometry.";
RL   Biochemistry 31:11138-11143(1992).
RN   [5]
RP   FUNCTION, CATALYTIC ACTIVITY, AND SUBCELLULAR LOCATION.
RX   PubMed=10684867; DOI=10.1523/jneurosci.20-05-01657.2000;
RA   Vekrellis K., Ye Z., Qiu W.Q., Walsh D., Hartley D., Chesneau V.,
RA   Rosner M.R., Selkoe D.J.;
RT   "Neurons regulate extracellular levels of amyloid beta-protein via
RT   proteolysis by insulin-degrading enzyme.";
RL   J. Neurosci. 20:1657-1665(2000).
RN   [6]
RP   FUNCTION, AND ACTIVITY REGULATION.
RX   PubMed=12941771; DOI=10.2337/diabetes.52.9.2315;
RA   Bennett R.G., Hamel F.G., Duckworth W.C.;
RT   "An insulin-degrading enzyme inhibitor decreases amylin degradation,
RT   increases amylin-induced cytotoxicity, and increases amyloid formation in
RT   insulinoma cell cultures.";
RL   Diabetes 52:2315-2320(2003).
RN   [7]
RP   FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION, SUBUNIT, AND MUTAGENESIS
RP   OF GLU-111 AND HIS-112.
RX   PubMed=14527953; DOI=10.1074/jbc.m308983200;
RA   Song E.S., Juliano M.A., Juliano L., Hersh L.B.;
RT   "Substrate activation of insulin-degrading enzyme (insulysin). A potential
RT   target for drug development.";
RL   J. Biol. Chem. 278:49789-49794(2003).
RN   [8]
RP   X-RAY CRYSTALLOGRAPHY (2.08 ANGSTROMS) OF 42-1019 OF WILD TYPE AND MUTANT
RP   PHE-111, CATALYTIC ACTIVITY, COFACTOR, ZINC-BINDING SITES, ACTIVITY
RP   REGULATION, ALLOSTERIC REGULATION, AND MUTAGENESIS OF GLU-111; VAL-360;
RP   ILE-374 AND TYR-609.
RX   PubMed=21731629; DOI=10.1371/journal.pone.0020864;
RA   Noinaj N., Bhasin S.K., Song E.S., Scoggin K.E., Juliano M.A., Juliano L.,
RA   Hersh L.B., Rodgers D.W.;
RT   "Identification of the allosteric regulatory site of insulysin.";
RL   PLoS ONE 6:E20864-E20864(2011).
RN   [9]
RP   X-RAY CRYSTALLOGRAPHY (2.27 ANGSTROMS), ATP-BINDING SITE, FUNCTION,
RP   CATALYTIC ACTIVITY, ACTIVITY REGULATION, AND MUTAGENESIS OF ARG-429;
RP   LYS-898; LYS-899 AND SER-901.
RX   PubMed=22049080; DOI=10.1074/jbc.m111.264614;
RA   Noinaj N., Song E.S., Bhasin S., Alper B.J., Schmidt W.K., Hersh L.B.,
RA   Rodgers D.W.;
RT   "Anion activation site of insulin-degrading enzyme.";
RL   J. Biol. Chem. 287:48-57(2012).
CC   -!- FUNCTION: Plays a role in the cellular breakdown of insulin, APP
CC       peptides, IAPP peptides, natriuretic peptides, glucagon, bradykinin,
CC       kallidin, and other peptides, and thereby plays a role in intercellular
CC       peptide signaling (PubMed:10684867, PubMed:12941771, PubMed:1445854,
CC       PubMed:14527953, PubMed:1836994, PubMed:22049080). Substrate binding
CC       induces important conformation changes, making it possible to bind and
CC       degrade larger substrates, such as insulin (By similarity). Contributes
CC       to the regulation of peptide hormone signaling cascades and regulation
CC       of blood glucose homeostasis via its role in the degradation of
CC       insulin, glucagon and IAPP (By similarity). Plays a role in the
CC       degradation and clearance of APP-derived amyloidogenic peptides that
CC       are secreted by neurons and microglia (PubMed:10684867). Degrades the
CC       natriuretic peptides ANP, BNP and CNP, inactivating their ability to
CC       raise intracellular cGMP (By similarity). Also degrades an aberrant
CC       frameshifted 40-residue form of NPPA (fsNPPA) which is associated with
CC       familial atrial fibrillation in heterozygous patients (By similarity).
CC       Involved in antigen processing. Produces both the N terminus and the C
CC       terminus of MAGEA3-derived antigenic peptide (EVDPIGHLY) that is
CC       presented to cytotoxic T lymphocytes by MHC class I.
CC       {ECO:0000250|UniProtKB:P14735, ECO:0000250|UniProtKB:Q9JHR7,
CC       ECO:0000269|PubMed:10684867, ECO:0000269|PubMed:12941771,
CC       ECO:0000269|PubMed:1445854, ECO:0000269|PubMed:14527953,
CC       ECO:0000269|PubMed:1836994, ECO:0000269|PubMed:22049080}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=Degradation of insulin, glucagon and other polypeptides. No
CC         action on proteins.; EC=3.4.24.56;
CC         Evidence={ECO:0000269|PubMed:10684867, ECO:0000269|PubMed:1445854,
CC         ECO:0000269|PubMed:14527953, ECO:0000269|PubMed:1836994,
CC         ECO:0000269|PubMed:21731629, ECO:0000269|PubMed:22049080};
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105;
CC         Evidence={ECO:0000269|PubMed:21731629};
CC       Note=Binds 1 zinc ion per subunit. {ECO:0000269|PubMed:21731629};
CC   -!- ACTIVITY REGULATION: Activated by ATP, other nucleotide triphosphates
CC       and small peptides (PubMed:14527953, PubMed:21731629, PubMed:22049080).
CC       Inhibited by bacitracin (PubMed:12941771).
CC       {ECO:0000269|PubMed:12941771, ECO:0000269|PubMed:14527953,
CC       ECO:0000269|PubMed:21731629, ECO:0000269|PubMed:22049080}.
CC   -!- SUBUNIT: Homodimer. Can also form homotetramers.
CC       {ECO:0000269|PubMed:14527953}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytosol {ECO:0000269|PubMed:10684867,
CC       ECO:0000269|PubMed:1836994}. Cell membrane
CC       {ECO:0000269|PubMed:10684867}. Secreted {ECO:0000269|PubMed:10684867}.
CC   -!- TISSUE SPECIFICITY: Detected in brain (at protein level).
CC       {ECO:0000269|PubMed:1836994}.
CC   -!- DOMAIN: The SlyX motif may be involved in the non-conventional
CC       secretion of the protein. {ECO:0000250|UniProtKB:Q9JHR7}.
CC   -!- MISCELLANEOUS: ATP-binding induces a conformation change.
CC       {ECO:0000250|UniProtKB:P14735}.
CC   -!- SIMILARITY: Belongs to the peptidase M16 family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X67269; CAA47689.1; -; mRNA.
DR   EMBL; S53721; AAB25205.1; -; mRNA.
DR   PIR; S29509; S29509.
DR   RefSeq; NP_037291.1; NM_013159.1.
DR   PDB; 3P7L; X-ray; 2.08 A; A=42-1019.
DR   PDB; 3P7O; X-ray; 2.14 A; A=1-1019.
DR   PDB; 3TUV; X-ray; 2.27 A; A=1-1019.
DR   PDBsum; 3P7L; -.
DR   PDBsum; 3P7O; -.
DR   PDBsum; 3TUV; -.
DR   AlphaFoldDB; P35559; -.
DR   SMR; P35559; -.
DR   BioGRID; 247729; 3.
DR   IntAct; P35559; 1.
DR   STRING; 10116.ENSRNOP00000023342; -.
DR   MEROPS; M16.002; -.
DR   iPTMnet; P35559; -.
DR   PhosphoSitePlus; P35559; -.
DR   jPOST; P35559; -.
DR   PaxDb; 10116-ENSRNOP00000023342; -.
DR   Ensembl; ENSRNOT00055047407; ENSRNOP00055038987; ENSRNOG00055027358.
DR   Ensembl; ENSRNOT00065048381; ENSRNOP00065039691; ENSRNOG00065028018.
DR   GeneID; 25700; -.
DR   KEGG; rno:25700; -.
DR   UCSC; RGD:2861; rat.
DR   AGR; RGD:2861; -.
DR   CTD; 3416; -.
DR   RGD; 2861; Ide.
DR   VEuPathDB; HostDB:ENSRNOG00000016833; -.
DR   eggNOG; KOG0959; Eukaryota.
DR   InParanoid; P35559; -.
DR   OrthoDB; 129328at2759; -.
DR   PhylomeDB; P35559; -.
DR   TreeFam; TF106275; -.
DR   BRENDA; 3.4.24.56; 5301.
DR   Reactome; R-RNO-5689880; Ub-specific processing proteases.
DR   Reactome; R-RNO-77387; Insulin receptor recycling.
DR   Reactome; R-RNO-9033241; Peroxisomal protein import.
DR   SABIO-RK; P35559; -.
DR   EvolutionaryTrace; P35559; -.
DR   PRO; PR:P35559; -.
DR   Proteomes; UP000002494; Chromosome 1.
DR   Bgee; ENSRNOG00000016833; Expressed in esophagus and 20 other cell types or tissues.
DR   ExpressionAtlas; P35559; baseline and differential.
DR   GO; GO:0016323; C:basolateral plasma membrane; ISO:RGD.
DR   GO; GO:0009986; C:cell surface; IDA:ARUK-UCL.
DR   GO; GO:0005737; C:cytoplasm; ISO:RGD.
DR   GO; GO:0005829; C:cytosol; ISO:RGD.
DR   GO; GO:0031597; C:cytosolic proteasome complex; IDA:RGD.
DR   GO; GO:0031904; C:endosome lumen; ISO:RGD.
DR   GO; GO:0009897; C:external side of plasma membrane; ISO:RGD.
DR   GO; GO:0070062; C:extracellular exosome; ISO:RGD.
DR   GO; GO:0005615; C:extracellular space; IDA:ARUK-UCL.
DR   GO; GO:0005739; C:mitochondrion; ISO:RGD.
DR   GO; GO:0005634; C:nucleus; ISO:RGD.
DR   GO; GO:0005782; C:peroxisomal matrix; IDA:RGD.
DR   GO; GO:0005777; C:peroxisome; ISO:RGD.
DR   GO; GO:0001540; F:amyloid-beta binding; IPI:RGD.
DR   GO; GO:0005524; F:ATP binding; IMP:RGD.
DR   GO; GO:0016887; F:ATP hydrolysis activity; IDA:RGD.
DR   GO; GO:0031626; F:beta-endorphin binding; IMP:RGD.
DR   GO; GO:0004175; F:endopeptidase activity; ISO:RGD.
DR   GO; GO:0042802; F:identical protein binding; IPI:RGD.
DR   GO; GO:0043559; F:insulin binding; IMP:RGD.
DR   GO; GO:0004222; F:metalloendopeptidase activity; IDA:RGD.
DR   GO; GO:0008233; F:peptidase activity; TAS:RGD.
DR   GO; GO:0042277; F:peptide binding; ISO:RGD.
DR   GO; GO:0017046; F:peptide hormone binding; IPI:RGD.
DR   GO; GO:0042803; F:protein homodimerization activity; ISO:RGD.
DR   GO; GO:0044877; F:protein-containing complex binding; IDA:RGD.
DR   GO; GO:0008270; F:zinc ion binding; IMP:RGD.
DR   GO; GO:0097242; P:amyloid-beta clearance; IMP:ARUK-UCL.
DR   GO; GO:0150094; P:amyloid-beta clearance by cellular catabolic process; IMP:ARUK-UCL.
DR   GO; GO:0050435; P:amyloid-beta metabolic process; IMP:RGD.
DR   GO; GO:0019885; P:antigen processing and presentation of endogenous peptide antigen via MHC class I; ISS:UniProtKB.
DR   GO; GO:0010815; P:bradykinin catabolic process; ISS:UniProtKB.
DR   GO; GO:0042447; P:hormone catabolic process; IDA:RGD.
DR   GO; GO:1901143; P:insulin catabolic process; ISS:UniProtKB.
DR   GO; GO:1901142; P:insulin metabolic process; ISO:RGD.
DR   GO; GO:0038020; P:insulin receptor recycling; ISO:RGD.
DR   GO; GO:0045861; P:negative regulation of proteolysis; IDA:RGD.
DR   GO; GO:0043171; P:peptide catabolic process; ISS:UniProtKB.
DR   GO; GO:0030163; P:protein catabolic process; IDA:RGD.
DR   GO; GO:0006508; P:proteolysis; ISO:RGD.
DR   GO; GO:0051603; P:proteolysis involved in protein catabolic process; IMP:RGD.
DR   GO; GO:1903715; P:regulation of aerobic respiration; ISO:RGD.
DR   GO; GO:0006979; P:response to oxidative stress; ISO:RGD.
DR   GO; GO:0010992; P:ubiquitin recycling; ISO:RGD.
DR   Gene3D; 3.30.830.10; Metalloenzyme, LuxS/M16 peptidase-like; 4.
DR   InterPro; IPR011249; Metalloenz_LuxS/M16.
DR   InterPro; IPR011765; Pept_M16_N.
DR   InterPro; IPR001431; Pept_M16_Zn_BS.
DR   InterPro; IPR050626; Peptidase_M16.
DR   InterPro; IPR007863; Peptidase_M16_C.
DR   InterPro; IPR032632; Peptidase_M16_M.
DR   PANTHER; PTHR43690:SF18; INSULIN-DEGRADING ENZYME-RELATED; 1.
DR   PANTHER; PTHR43690; NARDILYSIN; 1.
DR   Pfam; PF00675; Peptidase_M16; 1.
DR   Pfam; PF05193; Peptidase_M16_C; 1.
DR   Pfam; PF16187; Peptidase_M16_M; 1.
DR   Pfam; PF22456; PqqF-like_C_4; 1.
DR   SUPFAM; SSF63411; LuxS/MPP-like metallohydrolase; 4.
DR   PROSITE; PS00143; INSULINASE; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Allosteric enzyme; ATP-binding; Cell membrane; Cytoplasm;
KW   Direct protein sequencing; Hydrolase; Membrane; Metal-binding;
KW   Metalloprotease; Nucleotide-binding; Protease; Reference proteome;
KW   Secreted; Zinc.
FT   CHAIN           1..1019
FT                   /note="Insulin-degrading enzyme"
FT                   /id="PRO_0000074406"
FT   MOTIF           853..858
FT                   /note="SlyX motif"
FT                   /evidence="ECO:0000250|UniProtKB:Q9JHR7"
FT   ACT_SITE        111
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU10096"
FT   BINDING         108
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000269|PubMed:21731629,
FT                   ECO:0007744|PDB:3P7L"
FT   BINDING         112
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000269|PubMed:21731629,
FT                   ECO:0007744|PDB:3P7L"
FT   BINDING         189
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000269|PubMed:21731629,
FT                   ECO:0007744|PDB:3P7L"
FT   BINDING         359..363
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000250|UniProtKB:P14735"
FT   BINDING         429
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000269|PubMed:22049080,
FT                   ECO:0007744|PDB:3TUV"
FT   BINDING         895..901
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000269|PubMed:22049080,
FT                   ECO:0007744|PDB:3TUV"
FT   MOD_RES         192
FT                   /note="N6-succinyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9JHR7"
FT   MOD_RES         697
FT                   /note="N6-succinyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9JHR7"
FT   MUTAGEN         111
FT                   /note="E->F: Expected to abolish catalytic activity."
FT                   /evidence="ECO:0000269|PubMed:21731629"
FT   MUTAGEN         111
FT                   /note="E->V: Abolishes catalytic activity. No effect on
FT                   substrate binding."
FT                   /evidence="ECO:0000269|PubMed:14527953"
FT   MUTAGEN         112
FT                   /note="H->Q: Abolishes catalytic activity. Decreases
FT                   substrate binding affinity."
FT                   /evidence="ECO:0000269|PubMed:14527953"
FT   MUTAGEN         360
FT                   /note="V->S: Strongly reduced catalytic activity. Strongly
FT                   reduced stimulation of activity by ATP."
FT                   /evidence="ECO:0000269|PubMed:21731629"
FT   MUTAGEN         374
FT                   /note="I->S: Strongly reduced catalytic activity. Abolishes
FT                   stimulation of activity by ATP."
FT                   /evidence="ECO:0000269|PubMed:21731629"
FT   MUTAGEN         429
FT                   /note="R->S: Greatly decreased activation by polyphosphate
FT                   anions."
FT                   /evidence="ECO:0000269|PubMed:22049080"
FT   MUTAGEN         609
FT                   /note="Y->F: Strongly reduced catalytic activity. Abolishes
FT                   stimulation of activity by ATP."
FT                   /evidence="ECO:0000269|PubMed:21731629"
FT   MUTAGEN         898
FT                   /note="K->A: Greatly decreased activation by polyphosphate
FT                   anions, and deficient in activation by small peptides; when
FT                   associated with A-899 and A-901."
FT                   /evidence="ECO:0000269|PubMed:22049080"
FT   MUTAGEN         899
FT                   /note="K->A: Greatly decreased activation by polyphosphate
FT                   anions, and deficient in activation by small peptides; when
FT                   associated with A-898 and A-901."
FT                   /evidence="ECO:0000269|PubMed:22049080"
FT   MUTAGEN         901
FT                   /note="S->A: Greatly decreased activation by polyphosphate
FT                   anions, and deficient in activation by small peptides; when
FT                   associated with A-898 and A-899."
FT                   /evidence="ECO:0000269|PubMed:22049080"
FT   STRAND          47..51
FT                   /evidence="ECO:0007829|PDB:3P7L"
FT   STRAND          63..69
FT                   /evidence="ECO:0007829|PDB:3P7L"
FT   STRAND          74..79
FT                   /evidence="ECO:0007829|PDB:3P7L"
FT   STRAND          84..93
FT                   /evidence="ECO:0007829|PDB:3P7L"
FT   HELIX           96..98
FT                   /evidence="ECO:0007829|PDB:3P7L"
FT   STRAND          101..103
FT                   /evidence="ECO:0007829|PDB:3P7O"
FT   HELIX           106..114
FT                   /evidence="ECO:0007829|PDB:3P7L"
FT   STRAND          118..121
FT                   /evidence="ECO:0007829|PDB:3P7L"
FT   HELIX           126..132
FT                   /evidence="ECO:0007829|PDB:3P7L"
FT   TURN            133..135
FT                   /evidence="ECO:0007829|PDB:3P7L"
FT   STRAND          137..142
FT                   /evidence="ECO:0007829|PDB:3P7L"
FT   STRAND          147..154
FT                   /evidence="ECO:0007829|PDB:3P7L"
FT   HELIX           155..157
FT                   /evidence="ECO:0007829|PDB:3P7L"
FT   HELIX           158..166
FT                   /evidence="ECO:0007829|PDB:3P7L"
FT   HELIX           167..169
FT                   /evidence="ECO:0007829|PDB:3P7L"
FT   HELIX           176..194
FT                   /evidence="ECO:0007829|PDB:3P7L"
FT   HELIX           197..206
FT                   /evidence="ECO:0007829|PDB:3P7L"
FT   STRAND          211..213
FT                   /evidence="ECO:0007829|PDB:3TUV"
FT   HELIX           214..216
FT                   /evidence="ECO:0007829|PDB:3P7L"
FT   HELIX           223..226
FT                   /evidence="ECO:0007829|PDB:3P7L"
FT   HELIX           228..232
FT                   /evidence="ECO:0007829|PDB:3P7L"
FT   HELIX           237..248
FT                   /evidence="ECO:0007829|PDB:3P7L"
FT   HELIX           251..253
FT                   /evidence="ECO:0007829|PDB:3P7L"
FT   STRAND          254..262
FT                   /evidence="ECO:0007829|PDB:3P7L"
FT   HELIX           264..275
FT                   /evidence="ECO:0007829|PDB:3P7L"
FT   HELIX           295..297
FT                   /evidence="ECO:0007829|PDB:3P7L"
FT   STRAND          298..305
FT                   /evidence="ECO:0007829|PDB:3P7L"
FT   STRAND          307..309
FT                   /evidence="ECO:0007829|PDB:3TUV"
FT   STRAND          312..320
FT                   /evidence="ECO:0007829|PDB:3P7L"
FT   HELIX           323..325
FT                   /evidence="ECO:0007829|PDB:3P7L"
FT   TURN            326..328
FT                   /evidence="ECO:0007829|PDB:3P7L"
FT   HELIX           330..338
FT                   /evidence="ECO:0007829|PDB:3P7L"
FT   HELIX           346..352
FT                   /evidence="ECO:0007829|PDB:3P7L"
FT   STRAND          355..367
FT                   /evidence="ECO:0007829|PDB:3P7L"
FT   STRAND          370..379
FT                   /evidence="ECO:0007829|PDB:3P7L"
FT   HELIX           381..385
FT                   /evidence="ECO:0007829|PDB:3P7L"
FT   HELIX           387..404
FT                   /evidence="ECO:0007829|PDB:3P7L"
FT   HELIX           408..423
FT                   /evidence="ECO:0007829|PDB:3P7L"
FT   HELIX           430..440
FT                   /evidence="ECO:0007829|PDB:3P7L"
FT   TURN            441..443
FT                   /evidence="ECO:0007829|PDB:3P7L"
FT   HELIX           446..448
FT                   /evidence="ECO:0007829|PDB:3P7L"
FT   TURN            449..454
FT                   /evidence="ECO:0007829|PDB:3P7L"
FT   HELIX           461..470
FT                   /evidence="ECO:0007829|PDB:3P7L"
FT   HELIX           473..475
FT                   /evidence="ECO:0007829|PDB:3P7L"
FT   STRAND          477..481
FT                   /evidence="ECO:0007829|PDB:3P7L"
FT   HELIX           483..485
FT                   /evidence="ECO:0007829|PDB:3P7L"
FT   TURN            494..496
FT                   /evidence="ECO:0007829|PDB:3P7L"
FT   STRAND          499..504
FT                   /evidence="ECO:0007829|PDB:3P7L"
FT   HELIX           507..514
FT                   /evidence="ECO:0007829|PDB:3P7L"
FT   STRAND          549..553
FT                   /evidence="ECO:0007829|PDB:3P7L"
FT   STRAND          555..563
FT                   /evidence="ECO:0007829|PDB:3P7L"
FT   STRAND          570..579
FT                   /evidence="ECO:0007829|PDB:3P7L"
FT   HELIX           581..583
FT                   /evidence="ECO:0007829|PDB:3P7L"
FT   STRAND          584..586
FT                   /evidence="ECO:0007829|PDB:3P7O"
FT   HELIX           587..613
FT                   /evidence="ECO:0007829|PDB:3P7L"
FT   STRAND          616..622
FT                   /evidence="ECO:0007829|PDB:3P7L"
FT   STRAND          624..635
FT                   /evidence="ECO:0007829|PDB:3P7L"
FT   HELIX           638..650
FT                   /evidence="ECO:0007829|PDB:3P7L"
FT   HELIX           656..672
FT                   /evidence="ECO:0007829|PDB:3P7L"
FT   HELIX           673..675
FT                   /evidence="ECO:0007829|PDB:3P7L"
FT   HELIX           678..690
FT                   /evidence="ECO:0007829|PDB:3P7L"
FT   STRAND          691..693
FT                   /evidence="ECO:0007829|PDB:3P7L"
FT   HELIX           697..704
FT                   /evidence="ECO:0007829|PDB:3P7L"
FT   HELIX           709..721
FT                   /evidence="ECO:0007829|PDB:3P7L"
FT   STRAND          722..732
FT                   /evidence="ECO:0007829|PDB:3P7L"
FT   HELIX           735..753
FT                   /evidence="ECO:0007829|PDB:3P7L"
FT   HELIX           760..762
FT                   /evidence="ECO:0007829|PDB:3P7L"
FT   STRAND          775..782
FT                   /evidence="ECO:0007829|PDB:3P7L"
FT   STRAND          787..799
FT                   /evidence="ECO:0007829|PDB:3P7L"
FT   HELIX           802..823
FT                   /evidence="ECO:0007829|PDB:3P7L"
FT   TURN            824..827
FT                   /evidence="ECO:0007829|PDB:3P7L"
FT   STRAND          833..840
FT                   /evidence="ECO:0007829|PDB:3P7L"
FT   STRAND          843..854
FT                   /evidence="ECO:0007829|PDB:3P7L"
FT   HELIX           856..875
FT                   /evidence="ECO:0007829|PDB:3P7L"
FT   HELIX           879..894
FT                   /evidence="ECO:0007829|PDB:3P7L"
FT   HELIX           900..912
FT                   /evidence="ECO:0007829|PDB:3P7L"
FT   HELIX           920..929
FT                   /evidence="ECO:0007829|PDB:3P7L"
FT   HELIX           933..943
FT                   /evidence="ECO:0007829|PDB:3P7L"
FT   STRAND          952..959
FT                   /evidence="ECO:0007829|PDB:3P7L"
FT   STRAND          990..993
FT                   /evidence="ECO:0007829|PDB:3P7L"
FT   HELIX           995..1000
FT                   /evidence="ECO:0007829|PDB:3P7L"
SQ   SEQUENCE   1019 AA;  117710 MW;  9DB297A7F1877CEC CRC64;
     MRNGLVWLLH PALPSTLHSI LGARPPPVKR LCGFPKQIYS TMNNPAIQRI EDHIVKSPED
     KREYRGLELA NGIKVLLISD PTTDKSSAAL DVHIGSLSDP PNIPGLSHFC EHMLFLGTKK
     YPKENEYSQF LSEHAGSSNA FTSGEHTNYY FDVSHEHLEG ALDRFAQFFL CPLFDASCKD
     REVNAVDSEH EKNVMNDAWR LFQLEKATGN PKHPFSKFGT GNKYTLETRP NQEGIDVREE
     LLKFHSTYYS SNLMAICVLG RESLDDLTNL VVKLFSEVEN KNVPLPEFPE HPFQEEHLKQ
     LYKIVPIKDI RNLYVTFPIP DLQQYYKSNP GHYLGHLIGH EGPGSLLSEL KSKGWVNTLV
     GGQKEGARGF MFFIINVDLT EEGLLHVEDI ILHMFQYIQK LRAEGPQEWV FQECKDLNAV
     AFRFKDKERP RGYTSKIAGK LHYYPLNGVL TAEYLLEEFR PDLIDMVLDK LRPENVRVAI
     VSKSFEGKTD RTEQWYGTQY KQEAIPEDVI QKWQNADLNG KFKLPTKNEF IPTNFEILAL
     EKDATPYPAL IKDTAMSKLW FKQDDKFFLP KACLNFEFFS PFAYVDPLHC NMAYLYLELL
     KDSLNEYAYA AELAGLSYDL QNTIYGMYLS VKGYNDKQPI LLKKITEKMA TFEIDKKRFE
     IIKEAYMRSL NNFRAEQPHQ HAMYYLRLLM TEVAWTKDEL KEALDDVTLP RLKAFIPQLL
     SRLHIEALLH GNITKQAALG VMQMVEDTLI EHAHTKPLLP SQLVRYREVQ LPDRGWFVYQ
     RRNEVHNNCG IEIYYQTDMQ STSENMFLEL FCQIISEPCF NTLRTKEQLG YIVFSGPRRA
     NGIQGLRFII QSEKPPHYLE SRVEAFLITM EKAIEDMTEE AFQKHIQALA IRRLDKPKKL
     SAECAKYWGE IISQQYNYDR DNIEVAYLKT LSKDDIIKFY KEMLAVDAPR RHKVSVHVLA
     REMDSCPVVG EFPSQNDINL SEAPPLPQPE VIHNMTEFKR GLPLFPLVKP HINFMAAKL
//
